{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,13]],"date-time":"2026-10-13T06:18:21Z","timestamp":1791872301679,"version":"4.3.4"},"reference-count":59,"publisher":"Springer Science and Business Media LLC","issue":"11","license":[{"start":{"date-parts":[[2018,9,19]],"date-time":"2018-09-19T00:00:00Z","timestamp":1537315200000},"content-version":"tdm","delay-in-days":0,"URL":"http:\/\/www.springer.com\/tdm"}],"funder":[{"name":"National Center for Research Resources (US), a component of the National Institutes of Health (NIH), and NIH Roadmap for Medical Research","award":["MO1RR00083-44 and UL1 RR024131-01, NIDA DA14935 and DA12393"],"award-info":[{"award-number":["MO1RR00083-44 and UL1 RR024131-01, NIDA DA14935 and DA12393"]}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Psychopharmacology"],"published-print":{"date-parts":[[2018,11]]},"DOI":"10.1007\/s00213-018-5025-2","type":"journal-article","created":{"date-parts":[[2018,9,19]],"date-time":"2018-09-19T16:08:50Z","timestamp":1537373330000},"page":"3223-3232","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":18,"title":["Effect of \u03b3-hydroxybutyrate (GHB) on driving as measured by a driving simulator"],"prefix":"10.1007","volume":"235","author":[{"given":"Evangelia","family":"Liakoni","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Delia A.","family":"Dempsey","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Matthew","family":"Meyers","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nancy G.","family":"Murphy","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Dary","family":"Fiorentino","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Christopher","family":"Havel","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Christine","family":"Haller","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Neal L.","family":"Benowitz","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2018,9,19]]},"reference":[{"issue":"6","key":"5025_CR1","doi-asserted-by":"publisher","first-page":"625","DOI":"10.1097\/jcp.0b013e31815a2542","volume":"27","author":"S Abanades","year":"2007","unstructured":"Abanades S, Farr\u00e9 M, Barral D, Torrens M, Closas N, Langohr K, Pastor A, de la Torre R (2007) Relative abuse liability of gamma-hydroxybutyric acid, flunitrazepam, and ethanol in club drug users. J Clin Psychopharmacol 27(6):625\u2013638","journal-title":"J Clin Psychopharmacol"},{"issue":"6","key":"5025_CR2","doi-asserted-by":"publisher","first-page":"843","DOI":"10.1212\/01.wnl.0000171749.71919.fa","volume":"65","author":"AE Akinwuntan","year":"2005","unstructured":"Akinwuntan AE, De Weerdt W, Feys H, Pauwels J, Baten G, Arno P, Kiekens C (2005) Effect of simulator training on driving after stroke: a randomized controlled trial. Neurology 65(6):843\u2013850","journal-title":"Neurology"},{"issue":"10","key":"5025_CR3","doi-asserted-by":"publisher","first-page":"987","DOI":"10.1007\/s00228-010-0870-x","volume":"66","author":"MS Al-Samarraie","year":"2010","unstructured":"Al-Samarraie MS, Karinen R, M\u00f8rland J, Stokke Opdal M (2010) Blood GHB concentrations and results of medical examinations in 25 car drivers in Norway. Eur J Clin Pharmacol 66(10):987\u2013998","journal-title":"Eur J Clin Pharmacol"},{"issue":"2","key":"5025_CR4","doi-asserted-by":"publisher","first-page":"177","DOI":"10.1016\/j.annemergmed.2005.10.012","volume":"47","author":"IB Anderson","year":"2006","unstructured":"Anderson IB, Kim SY, Dyer JE, Burkhardt CB, Iknoian JC, Walsh MJ, Blanc PD (2006) Trends in gamma-hydroxybutyrate (GHB) and related drug intoxication: 1999 to 2003. Ann Emerg Med 47(2):177\u2013183","journal-title":"Ann Emerg Med"},{"issue":"9","key":"5025_CR5","doi-asserted-by":"publisher","first-page":"1025","DOI":"10.1001\/jama.294.9.1025","volume":"294","author":"JT Arnedt","year":"2005","unstructured":"Arnedt JT, Owens J, Crouch M, Stahl J, Carskadon MA (2005) Neurobehavioral performance of residents after heavy night call vs after alcohol ingestion. JAMA 294(9):1025\u20131033","journal-title":"JAMA"},{"issue":"7","key":"5025_CR6","doi-asserted-by":"publisher","first-page":"697","DOI":"10.1197\/aemj.10.7.697","volume":"10","author":"TC Bania","year":"2003","unstructured":"Bania TC, Ashar T, Press G, Carey PM (2003) Gamma-hydroxybutyric acid tolerance and withdrawal in a rat model. Acad Emerg Med 10(7):697\u2013704","journal-title":"Acad Emerg Med"},{"issue":"6","key":"5025_CR7","doi-asserted-by":"publisher","first-page":"798","DOI":"10.1592\/phco.22.9.798.34063","volume":"22","author":"LA Borgen","year":"2002","unstructured":"Borgen LA, Cook HN, Hornfeldt CS, Fuller DE (2002) Sodium oxybate (GHB) for treatment of cataplexy. Pharmacotherapy 22(6):798\u2013799 discussion 799","journal-title":"Pharmacotherapy"},{"issue":"3","key":"5025_CR8","doi-asserted-by":"publisher","first-page":"253","DOI":"10.1177\/0091270003262795","volume":"44","author":"LA Borgen","year":"2004","unstructured":"Borgen LA, Okerholm RA, Lai A, Scharf MB (2004) The pharmacokinetics of sodium oxybate oral solution following acute and chronic administration to narcoleptic patients. J Clin Pharmacol 44(3):253\u2013257","journal-title":"J Clin Pharmacol"},{"key":"5025_CR9","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1016\/j.psyneuen.2015.07.167","volume":"62","author":"OG Bosch","year":"2015","unstructured":"Bosch OG, Eisenegger C, Gertsch J, von Rotz R, Dornbierer D, Gachet MS, Heinrichs M, Wetter TC, Seifritz E, Quednow BB (2015) Gamma-hydroxybutyrate enhances mood and prosocial behavior without affecting plasma oxytocin and testosterone. Psychoneuroendocrinology 62:1\u201310","journal-title":"Psychoneuroendocrinology"},{"issue":"1\u20132","key":"5025_CR10","doi-asserted-by":"publisher","first-page":"17","DOI":"10.1016\/S0379-0738(03)00044-6","volume":"133","author":"IJ Bosman","year":"2003","unstructured":"Bosman IJ, Lusthof KJ (2003) Forensic cases involving the use of GHB in The Netherlands. Forensic Sci Int 133(1\u20132):17\u201321","journal-title":"Forensic Sci Int"},{"issue":"8","key":"5025_CR11","doi-asserted-by":"publisher","first-page":"625","DOI":"10.1093\/jat\/28.8.625","volume":"28","author":"R Brenneisen","year":"2004","unstructured":"Brenneisen R, Elsohly MA, Murphy TP, Passarelli J, Russmann S, Salamone SJ, Watson DE (2004) Pharmacokinetics and excretion of gamma-hydroxybutyrate (GHB) in healthy subjects. J Anal Toxicol 28(8):625\u2013630","journal-title":"J Anal Toxicol"},{"issue":"4","key":"5025_CR12","doi-asserted-by":"publisher","first-page":"278","DOI":"10.1016\/j.jflm.2012.10.005","volume":"20","author":"HJ Burch","year":"2013","unstructured":"Burch HJ, Clarke EJ, Hubbard AM, Scott-Ham M (2013) Concentrations of drugs determined in blood samples collected from suspected drugged drivers in England and Wales. J Forensic Legal Med 20(4):278\u2013289","journal-title":"J Forensic Legal Med"},{"issue":"1","key":"5025_CR13","doi-asserted-by":"publisher","first-page":"47","DOI":"10.2174\/1570159X13666141210215423","volume":"13","author":"FP Busard\u00f2","year":"2015","unstructured":"Busard\u00f2 FP, Jones AW (2015) GHB pharmacology and toxicology: acute intoxication, concentrations in blood and urine in forensic cases and treatment of the withdrawal syndrome. Curr Neuropharmacol 13(1):47\u201370","journal-title":"Curr Neuropharmacol"},{"issue":"11","key":"5025_CR14","doi-asserted-by":"publisher","first-page":"2537","DOI":"10.1038\/sj.npp.1301146","volume":"31","author":"LP Carter","year":"2006","unstructured":"Carter LP, Richards BD, Mintzer MZ, Griffiths RR (2006) Relative abuse liability of GHB in humans: a comparison of psychomotor,subjective, and cognitive effects of supratherapeutic doses of triazolam,pentobarbital, and GHB. Neuropsychopharmacology 31(11):2537\u20132551","journal-title":"Neuropsychopharmacology"},{"issue":"1","key":"5025_CR15","doi-asserted-by":"publisher","first-page":"141","DOI":"10.1007\/s00213-009-1589-1","volume":"206","author":"LP Carter","year":"2009","unstructured":"Carter LP, Griffiths RR, Mintzer MZ (2009) Cognitive, psychomotor, and subjective effects of sodium oxybate and triazolam in healthy volunteers. Psychopharmacology 206(1):141\u2013154","journal-title":"Psychopharmacology"},{"key":"5025_CR16","doi-asserted-by":"publisher","unstructured":"Centola C, Giorgetti A, Zaami S, Giorgetti R (2018) Effects of GHB on psychomotor and driving performance. Curr Drug Metab. https:\/\/doi.org\/10.2174\/1389200219666180124113802","DOI":"10.2174\/1389200219666180124113802"},{"issue":"4","key":"5025_CR17","doi-asserted-by":"publisher","first-page":"919","DOI":"10.1520\/JFS15070J","volume":"46","author":"FJ Couper","year":"2001","unstructured":"Couper FJ, Logan BK (2001) GHB and driving impairment. J Forensic Sci 46(4):919\u2013923","journal-title":"J Forensic Sci"},{"issue":"6","key":"5025_CR18","doi-asserted-by":"publisher","first-page":"512","DOI":"10.1093\/jat\/28.6.512","volume":"28","author":"FJ Couper","year":"2004","unstructured":"Couper FJ, Logan BK (2004) Addicted to driving under the influence\u2014a GHB\/GBL case report. J Anal Toxicol 28(6):512\u2013515","journal-title":"J Anal Toxicol"},{"issue":"1\u20132","key":"5025_CR19","first-page":"101","volume":"14","author":"FJ Couper","year":"2002","unstructured":"Couper FJ, Marinetti LJ (2002) \u03b3-Hydroxybutyrate (GHB)\u2014effects on human performance and behavior. Forensic Sci Rev 14(1\u20132):101\u2013121","journal-title":"Forensic Sci Rev"},{"issue":"Supplement 1","key":"5025_CR20","first-page":"S51","volume":"81","author":"D Dempsey","year":"2007","unstructured":"Dempsey D, Murphy N, Benowitz NL, Wiegand T, Wu L, Haller CA (2007) Respiratory effects of gamma-hydroxybutyrate (GHB) and ethanol. Clin Pharm Ther 81(Supplement 1):S51","journal-title":"Clin Pharm Ther"},{"issue":"3","key":"5025_CR21","doi-asserted-by":"publisher","first-page":"145","DOI":"10.1111\/j.1600-0404.2006.00712.x","volume":"114","author":"KR Drasbek","year":"2006","unstructured":"Drasbek KR, Christensen J, Jensen K (2006) Gamma-hydroxybutyrate\u2014a drug of abuse. Acta Neurol Scand 114(3):145\u2013156","journal-title":"Acta Neurol Scand"},{"issue":"2\u20133","key":"5025_CR22","doi-asserted-by":"publisher","first-page":"112","DOI":"10.1016\/j.forsciint.2007.02.009","volume":"173","author":"S Dresen","year":"2007","unstructured":"Dresen S, Kempf J, Weinmann W (2007) Prevalence of gamma-hydroxybutyrate (GHB) in serum samples of amphetamine, metamphetamine and ecstasy impaired drivers. Forensic Sci Int 173(2\u20133):112\u2013116","journal-title":"Forensic Sci Int"},{"issue":"3","key":"5025_CR23","doi-asserted-by":"publisher","first-page":"141","DOI":"10.1093\/jat\/23.3.141","volume":"23","author":"MA ElSohly","year":"1999","unstructured":"ElSohly MA, Salamone SJ (1999) Prevalence of drugs used in cases of alleged sexual assault. J Anal Toxicol 23(3):141\u2013146","journal-title":"J Anal Toxicol"},{"key":"5025_CR24","unstructured":"European Monitoring Centre for Drugs and Drug Addiction (EMCDDA) (2008) GHB and its precursor GBL: an emerging trend case study. http:\/\/wwwemcddaeuropaeu\/system\/files\/publications\/505\/TP_GHB_and_GBL_107300pdf Accessed June 2018"},{"issue":"11","key":"5025_CR25","doi-asserted-by":"publisher","first-page":"821","DOI":"10.1007\/s002280050560","volume":"54","author":"SD Ferrara","year":"1999","unstructured":"Ferrara SD, Giorgetti R, Zancaner S, Orlando R, Tagliabracci A, Cavarzeran F, Palatini P (1999) Effects of single dose of gamma-hydroxybutyric acid and lorazepam on psychomotor performance and subjective feelings in healthy volunteers. Eur J Clin Pharmacol 54(11):821\u2013827","journal-title":"Eur J Clin Pharmacol"},{"issue":"1","key":"5025_CR26","doi-asserted-by":"publisher","first-page":"2","DOI":"10.1037\/a0024338","volume":"141","author":"CO Fritz","year":"2012","unstructured":"Fritz CO, Morris PE, Richler JJ (2012) Effect size estimates: current use, calculations, and interpretation. J Exp Psychol Gen 141(1):2\u201318","journal-title":"J Exp Psychol Gen"},{"issue":"12","key":"5025_CR27","doi-asserted-by":"publisher","first-page":"1967","DOI":"10.1212\/01.wnl.0000188670.38576.bd","volume":"65","author":"SJ Frucht","year":"2005","unstructured":"Frucht SJ, Houghton WC, Bordelon Y, Greene PE, Louis ED (2005) A single-blind, open-label trial of sodium oxybate for myoclonus and essential tremor. Neurology 65(12):1967\u20131969","journal-title":"Neurology"},{"issue":"5","key":"5025_CR28","doi-asserted-by":"publisher","first-page":"293","DOI":"10.2165\/00002018-200427050-00002","volume":"27","author":"DE Fuller","year":"2004","unstructured":"Fuller DE, Hornfeldt CS, Kelloway JS, Stahl PJ, Anderson TF (2004) The Xyrem risk management program. Drug Saf 27(5):293\u2013306","journal-title":"Drug Saf"},{"issue":"2","key":"5025_CR29","doi-asserted-by":"publisher","first-page":"195","DOI":"10.1177\/0269881105049041","volume":"19","author":"A Gonzalez","year":"2005","unstructured":"Gonzalez A, Nutt DJ (2005) Gamma hydroxy butyrate abuse and dependency. J Psychopharmacol 19(2):195\u2013204","journal-title":"J Psychopharmacol"},{"key":"5025_CR30","doi-asserted-by":"publisher","first-page":"451","DOI":"10.1111\/j.1749-6632.2002.tb04186.x","volume":"965","author":"Y Itzhak","year":"2002","unstructured":"Itzhak Y, Ali SF (2002) Repeated administration of gamma-hydroxybutyric acid (GHB) to mice: assessment of the sedative and rewarding effects of GHB. Ann N Y Acad Sci 965:451\u2013460","journal-title":"Ann N Y Acad Sci"},{"issue":"2","key":"5025_CR31","doi-asserted-by":"publisher","first-page":"112","DOI":"10.1037\/a0031692","volume":"21","author":"MW Johnson","year":"2013","unstructured":"Johnson MW, Griffiths RR (2013) Comparative abuse liability of GHB and ethanol in humans. Exp Clin Psychopharmacol 21(2):112\u2013123","journal-title":"Exp Clin Psychopharmacol"},{"issue":"9","key":"5025_CR32","doi-asserted-by":"publisher","first-page":"566","DOI":"10.1093\/jat\/31.9.566","volume":"31","author":"AW Jones","year":"2007","unstructured":"Jones AW, Holmgren A, Kugelberg FC (2007) Gamma-hydroxybutyrate concentrations in the blood of impaired drivers, users of illicit drugs, and medical examiner cases. J Anal Toxicol 31(9):566\u2013572","journal-title":"J Anal Toxicol"},{"issue":"1","key":"5025_CR33","doi-asserted-by":"publisher","first-page":"63","DOI":"10.1007\/s40261-013-0158-x","volume":"34","author":"GM Keating","year":"2014","unstructured":"Keating GM (2014) Sodium oxybate: a review of its use in alcohol withdrawal syndrome and in the maintenance of abstinence in alcohol dependence. Clin Drug Investig 34(1):63\u201380","journal-title":"Clin Drug Investig"},{"issue":"3","key":"5025_CR34","doi-asserted-by":"publisher","first-page":"271","DOI":"10.1016\/j.drugalcdep.2003.08.002","volume":"72","author":"MG Lenne","year":"2003","unstructured":"Lenne MG, Dietze P, Rumbold GR, Redman JR, Triggs TJ (2003) The effects of the opioid pharmacotherapies methadone, LAAM and buprenorphine, alone and in combination with alcohol, on simulated driving. Drug Alcohol Depend 72(3):271\u2013278","journal-title":"Drug Alcohol Depend"},{"issue":"1","key":"5025_CR35","doi-asserted-by":"publisher","first-page":"107","DOI":"10.1186\/s13049-016-0299-z","volume":"24","author":"E Liakoni","year":"2016","unstructured":"Liakoni E, Walther F, Nickel CH, Liechti ME (2016) Presentations to an urban emergency department in Switzerland due to acute \u03b3-hydroxybutyrate toxicity. Scand J Trauma Resusc Emerg Med 24(1):107","journal-title":"Scand J Trauma Resusc Emerg Med"},{"issue":"5","key":"5025_CR36","doi-asserted-by":"publisher","first-page":"980","DOI":"10.1111\/bcp.12863","volume":"81","author":"ME Liechti","year":"2016","unstructured":"Liechti ME, Quednow BB, Liakoni E, Dornbierer D, von Rotz R, Gachet MS, Gertsch J, Seifritz E, Bosch OG (2016) Pharmacokinetics and pharmacodynamics of \u03b3-hydroxybutyrate in healthy subjects. Br J Clin Pharmacol 81(5):980\u2013988","journal-title":"Br J Clin Pharmacol"},{"issue":"2","key":"5025_CR37","first-page":"236","volume":"234","author":"MJ Mattila","year":"1978","unstructured":"Mattila MJ, Palva E, Sepp\u00e4l\u00e4 T, Ostrovskaya RU (1978) Actions and interactions with alcohol of drugs on psychomotor skills: comparison of diazepam and gamma-hydroxybutyric acid. Arch Int Pharmacodyn Ther 234(2):236\u2013246","journal-title":"Arch Int Pharmacodyn Ther"},{"issue":"3","key":"5025_CR38","doi-asserted-by":"publisher","first-page":"262","DOI":"10.1002\/eat.20798","volume":"44","author":"SL McElroy","year":"2011","unstructured":"McElroy SL, Guerdjikova AI, Winstanley EL, O'Melia AM, Mori N, Jr Keck PE, Hudson JI (2011) Sodium oxybate in the treatment of binge eating disorder: an open-label, prospective study. Int J Eat Disord 44(3):262\u2013268","journal-title":"Int J Eat Disord"},{"key":"5025_CR39","doi-asserted-by":"publisher","first-page":"84","DOI":"10.1016\/j.toxlet.2017.05.030","volume":"277","author":"\u00d2 Mir\u00f3","year":"2017","unstructured":"Mir\u00f3 \u00d2, Galicia M, Dargan P, Dines AM, Giraudon I, Heyerdahl F, Hovda KE, Yates C, Wood DM, Euro-DEN Research Group (2017) Intoxication by gamma hydroxybutyrate and related analogues: clinical characteristics and comparison between pure intoxication and that combined with other substances of abuse. Toxicol Lett 277:84\u201391","journal-title":"Toxicol Lett"},{"key":"5025_CR40","unstructured":"Moskowitz H, Burns M, Fiorentino D, Smiley A, Zador P (2000) Driving characteristics and impairment at various BACs, DOT HS 809 075 (P. J. Tremont, ed.), US Department of Transportation, National Highway Traffice Safety Administration, pp. 1\u201360. www.nhtsa.dot.gov\/people\/injury\/research\/pub\/impaired_driving\/BAC\/impairment.pdf Accessed March 2018"},{"key":"5025_CR41","unstructured":"National Drug Intelligence Center (2002) Information bulletin: GHB analogs GBL, BD, GHV and GVL, National Drug Intelligence Center https:\/\/wwwjusticegov\/archive\/ndic\/pubs1\/1621\/1621thtm Accessed March 2018"},{"issue":"4","key":"5025_CR42","doi-asserted-by":"publisher","first-page":"332","DOI":"10.1097\/FBP.0b013e32833b3397","volume":"21","author":"A Oliveto","year":"2010","unstructured":"Oliveto A, Gentry WB, Pruzinsky R, Gonsai K, Kosten TR, Martell B, Poling J (2010) Behavioral effects of gamma-hydroxybutyrate in humans. Behav Pharmacol 21(4):332\u2013342","journal-title":"Behav Pharmacol"},{"issue":"4","key":"5025_CR43","doi-asserted-by":"publisher","first-page":"353","DOI":"10.1007\/BF00265954","volume":"45","author":"P Palatini","year":"1993","unstructured":"Palatini P, Tedeschi L, Frison G, Padrini R, Zordan R, Orlando R, Gallimberti L, Gessa GL, Ferrara SD (1993) Dose-dependent absorption and elimination of gamma-hydroxybutyric acid in healthy volunteers. Eur J Clin Pharmacol 45(4):353\u2013356","journal-title":"Eur J Clin Pharmacol"},{"issue":"5","key":"5025_CR44","doi-asserted-by":"publisher","first-page":"328","DOI":"10.1093\/jat\/25.5.328","volume":"25","author":"YM Pan","year":"2001","unstructured":"Pan YM, Gill GN, Tilson CS, Wall WH, McCurdy HH (2001) Improved procedure for the analysis of gamma-hydroxybutyrate and ethylene glycol in whole blood. J Anal Toxicol 25(5):328\u2013332","journal-title":"J Anal Toxicol"},{"issue":"6","key":"5025_CR45","doi-asserted-by":"publisher","first-page":"553","DOI":"10.1016\/j.sleep.2003.06.005","volume":"4","author":"M Partinen","year":"2003","unstructured":"Partinen M, Hirvonen K, Hublin C, Halavaara M, Hiltunen H (2003) Effects of after-midnight intake of zolpidem and temazepam on driving ability in women with non-organic insomnia. Sleep Med 4(6):553\u2013561","journal-title":"Sleep Med"},{"key":"5025_CR46","volume-title":"Oral solution, sodium oxybate oral solution","author":"Product Information: Xyrem\u00ae","year":"2012","unstructured":"Product Information: Xyrem\u00ae (2012) Oral solution, sodium oxybate oral solution. Jazz Pharmaceuticals (per FDA), Palo Alto"},{"issue":"6","key":"5025_CR47","doi-asserted-by":"publisher","first-page":"1402","DOI":"10.1002\/lary.26381","volume":"127","author":"AF Rumbach","year":"2017","unstructured":"Rumbach AF, Blitzer A, Frucht SJ, Simonyan K (2017) An open-label study of sodium oxybate in spasmodic dysphonia. Laryngoscope 127(6):1402\u20131407","journal-title":"Laryngoscope"},{"issue":"1","key":"5025_CR48","doi-asserted-by":"publisher","first-page":"299","DOI":"10.1002\/art.24142","volume":"60","author":"IJ Russell","year":"2009","unstructured":"Russell IJ, Perkins AT, Michalek JE (2009) Oxybate SXB-26 fibromyalgia syndrome. Sodium oxybate relieves pain and improves function in fibromyalgia syndrome: a randomized, double-blind, placebo-controlled, multicenter clinical trial. Arthritis Rheum 60(1):299\u2013309","journal-title":"Arthritis Rheum"},{"issue":"5","key":"5025_CR49","doi-asserted-by":"publisher","first-page":"507","DOI":"10.1093\/sleep\/21.5.507","volume":"21","author":"MB Scharf","year":"1998","unstructured":"Scharf MB, Lai AA, Branigan B, Stover R, Berkowitz DB (1998) Pharmacokinetics of gammahydroxybutyrate (GHB) in narcoleptic patients. Sleep 21(5):507\u2013514","journal-title":"Sleep"},{"issue":"6","key":"5025_CR50","doi-asserted-by":"publisher","first-page":"458","DOI":"10.3109\/15563650.2012.702218","volume":"50","author":"LJ Schep","year":"2012","unstructured":"Schep LJ, Knudsen K, Slaughter RJ, Vale JA, M\u00e9garbane B (2012) The clinical toxicology of \u03b3-hydroxybutyrate, \u03b3-butyrolactone and 1,4-butanediol. Clin Toxicol (Phila) 50(6):458\u2013470","journal-title":"Clin Toxicol (Phila)"},{"issue":"4","key":"5025_CR51","doi-asserted-by":"publisher","first-page":"363","DOI":"10.1002\/dta.1498","volume":"6","author":"A Schr\u00f6ck","year":"2014","unstructured":"Schr\u00f6ck A, Hari Y, K\u00f6nig S, Auw\u00e4rter V, Sch\u00fcrch S, Weinmann W (2014) Pharmacokinetics of GHB and detection window in serum and urine after single uptake of a low dose of GBL\u2014an experiment with two volunteers. Drug Test Anal 6(4):363\u2013366","journal-title":"Drug Test Anal"},{"issue":"26","key":"5025_CR52","doi-asserted-by":"publisher","first-page":"2721","DOI":"10.1056\/NEJMra044047","volume":"352","author":"OC Snead III","year":"2005","unstructured":"Snead OC III, Gibson KM (2005) Gamma-hydroxybutyric acid. N Engl J Med 352(26):2721\u20132732","journal-title":"N Engl J Med"},{"issue":"4","key":"5025_CR53","doi-asserted-by":"publisher","first-page":"790","DOI":"10.1007\/s00213-005-0082-8","volume":"181","author":"L Staner","year":"2005","unstructured":"Staner L, Ertle S, Boeijinga P, Rinaudo G, Arnal MA, Muzet A, Luthringer R (2005) Next-day residual effects of hypnotics in DSM-IV primary insomnia: a driving simulator study with simultaneous electroencephalogram monitoring. Psychopharmacology 181(4):790\u2013798","journal-title":"Psychopharmacology"},{"issue":"6","key":"5025_CR54","doi-asserted-by":"publisher","first-page":"357","DOI":"10.1093\/jat\/18.6.357","volume":"18","author":"BG Stephens","year":"1994","unstructured":"Stephens BG, Baselt RC (1994) Driving under the influence of GHB? J Anal Toxicol 18(6):357\u2013358","journal-title":"J Anal Toxicol"},{"issue":"5","key":"5025_CR55","doi-asserted-by":"publisher","first-page":"524","DOI":"10.1097\/01.jcp.0000237944.57893.28","volume":"26","author":"D Thai","year":"2006","unstructured":"Thai D, Dyer JE, Benowitz NL, Haller CA (2006) Gamma-hydroxybutyrate and ethanol effects and interactions in humans. J Clin Psychopharmacol 26(5):524\u2013529","journal-title":"J Clin Psychopharmacol"},{"issue":"2","key":"5025_CR56","doi-asserted-by":"publisher","first-page":"178","DOI":"10.1038\/sj.clpt.6100037","volume":"81","author":"D Thai","year":"2007","unstructured":"Thai D, Dyer JE, Jacob P, Haller CA (2007) Clinical pharmacology of 1,4-butanediol and gamma-hydroxybutyrate after oral 1,4-butanediol administration to healthy volunteers. Clin Pharmacol Ther 81(2):178\u2013184","journal-title":"Clin Pharmacol Ther"},{"issue":"10","key":"5025_CR57","doi-asserted-by":"publisher","first-page":"800","DOI":"10.1136\/thorax.56.10.800","volume":"56","author":"PM Turkington","year":"2001","unstructured":"Turkington PM, Sircar M, Allgar V, Elliott MW (2001) Relationship between obstructive sleep apnoea, driving simulator performance, and risk of road traffic accidents. Thorax 56(10):800\u2013805","journal-title":"Thorax"},{"issue":"3","key":"5025_CR58","doi-asserted-by":"crossref","first-page":"310","DOI":"10.5664\/JCSM.1082","volume":"7","author":"DM Wallace","year":"2011","unstructured":"Wallace DM, Maze T, Shafazand S (2011) Sodium oxybate-induced sleep driving and sleep-related eating disorder. J Clin Sleep Med 7(3):310\u2013311","journal-title":"J Clin Sleep Med"},{"issue":"5","key":"5025_CR59","doi-asserted-by":"publisher","first-page":"354","DOI":"10.7326\/0003-4819-132-5-200003070-00004","volume":"132","author":"JM Weiler","year":"2000","unstructured":"Weiler JM, Bloomfield JR, Woodworth GG, Grant AR, Layton TA, Brown TL, McKenzie DR, Baker TW, Watson GS (2000) Effects of fexofenadine, diphenhydramine, and alcohol on driving performance. A randomized, placebo-controlled trial in the Iowa driving simulator. Ann Intern Med 132(5):354\u2013363","journal-title":"Ann Intern Med"}],"container-title":["Psychopharmacology"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/link.springer.com\/article\/10.1007\/s00213-018-5025-2\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s00213-018-5025-2.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s00213-018-5025-2.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2020,11,10]],"date-time":"2020-11-10T07:16:27Z","timestamp":1604992587000},"score":1,"resource":{"primary":{"URL":"http:\/\/link.springer.com\/10.1007\/s00213-018-5025-2"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2018,9,19]]},"references-count":59,"journal-issue":{"issue":"11","published-print":{"date-parts":[[2018,11]]}},"alternative-id":["5025"],"URL":"https:\/\/doi.org\/10.1007\/s00213-018-5025-2","relation":{},"ISSN":["0033-3158","1432-2072"],"issn-type":[{"value":"0033-3158","type":"print"},{"value":"1432-2072","type":"electronic"}],"subject":[],"published":{"date-parts":[[2018,9,19]]},"assertion":[{"value":"25 April 2018","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"3 September 2018","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"19 September 2018","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"This study was performed with informed consent and with the approval of the Committee on Human Research of the University of California, San Francisco.","order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Compliance with ethical standards"}},{"value":"The authors declare that they have no conflict of interest.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of interest"}}]}}